Actively Recruiting
Observational Registry of Patients with AQP4 Neuromyelitis Optica Spectrum Disorder Receiving Alexion Complement Component 5 Inhibitor Therapies
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-10-13
200
Participants Needed
33
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing patients with Anti-Aquaporin 4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder AQP4 NMOSD to understand the real-world impact of Alexion Complement Component 5 Inhibitor Therapies ALXN-C5IT. This long-term, multicenter, multinational registry study collects data on clinical outcomes, safety, patient-reported outcomes, and quality of life in patients treated with these therapies. The study aims to provide evidence about how these treatments affect patients in everyday medical practice. Participants in the registry must be adults diagnosed with AQP4 NMOSD who have been prescribed ALXN-C5IT, such as eculizumab or ravulizumab, for chronic relapse prevention. At enrollment, retrospective data about medical history and therapy usage from one year before starting ALXN-C5IT until enrollment will be collected. The study does not administer treatments but tracks information from patients receiving these therapies according to local medical guidelines. Participants will be followed for up to approximately five years from the last enrollment date. During this time, researchers will collect ongoing clinical and safety data, including relapse rates, and monitor patient experiences and quality of life through questionnaires and other assessments. This observational approach helps understand long-term outcomes and safety in the real-world setting for patients using ALXN-C5IT therapies.
CONDITIONS
Brief Title
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Research Team
A
Alexion Pharmaceuticals, Inc. (Sponsor)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here